Dry Eye Dease
Conditions
Interventions
Observation group:None
Sponsors
Tianjin Medical University Eye Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age over 50 years, no restriction on gender; 2. At least one eye has decreased visual quality due to lens opacity affecting daily life, diagnosed with age-related cataract, and patient is 1 month post phacoemulsification cataract surgery with intraocular lens implantation; 3. Pupil diameter under bright vision >= 2.75mm, pupil diameter under dark vision >= 4mm, and normal pupillary light reflex; 4. Average central corneal refractive power 41.00-46.00D, and corneal astigmatism <= 1.00D; 5. Axial length 22.00-26.00mm, and no posterior scleral staphyloma; 6. Voluntarily participate in this trial and agree to sign the informed consent form; 7. No malignant tumor or systemic infection, general screening normal, including medical history and general physical examination.
Exclusion criteria
Exclusion criteria: 1. Any previous surgical history that may affect the ocular surface microenvironment, other than cataract surgery, or history of ocular trauma; 2. Subjects who have had (for any reason) conjunctivitis, keratitis, blepharitis, rosacea, allergic rhinitis, or significant corneal abnormalities (such as epithelial basement membrane disease), pterygium, etc., within the past 30 days; 3. Subjects who have used local or systemic antiglaucoma medications, as well as drugs affecting ocular surface function such as steroids, cyclosporine, atropine, neostigmine, artificial tears, etc., within the past 30 days; patients already diagnosed with dry eye and regularly using ocular lubricants are also excluded; 4. Subjects with a history of wearing corneal contact lenses within the past 30 days; 5. Combined with any ocular disease other than cataract that may alter the ocular surface microenvironment or corneal morphology, such as entropion, ectropion, eyelid deformities, corneal scars, irregular corneal astigmatism, etc.; 6. Participation in any other clinical trial within the past year; 7. Any other condition deemed by the investigator as unsuitable for participation in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tear Break-Up Time; | — |
Secondary
| Measure | Time frame |
|---|---|
| Corneal Fluorescein Staining Score;OSDI-6 score; | — |
Countries
China
Contacts
Public ContactFang Tian
Tianjin Medical University Eye Hospital
Outcome results
None listed